Advertisement
Research Article| Volume 71, ISSUE 4, P719-730, October 2019

Download started.

Ok

Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury

  • Author Footnotes
    † These authors contributed equally to this work.
    Yuan Liu
    Footnotes
    † These authors contributed equally to this work.
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA

    Department of Liver Surgery, Ren Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    † These authors contributed equally to this work.
    Tianfei Lu
    Footnotes
    † These authors contributed equally to this work.
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA

    Department of Liver Surgery, Ren Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Search for articles by this author
  • Author Footnotes
    † These authors contributed equally to this work.
    Cheng Zhang
    Footnotes
    † These authors contributed equally to this work.
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA

    Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
    Search for articles by this author
  • Jin Xu
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA

    Department of Pancreatic Surgery, Shengjing Hospital, China Medical University, Shenyang, China
    Search for articles by this author
  • Zhengze Xue
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA

    Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
    Search for articles by this author
  • Ronald W. Busuttil
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA
    Search for articles by this author
  • Ning Xu
    Correspondence
    Corresponding authors. Addresses: Dumont-UCLA Transplant Center, 77-120 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Tel.: +1 (323) 205-5156, (H. Ji), or Department of Liver Surgery, Ren Ji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Shanghai 200127, China (Q. Xia or N. Xu).
    Affiliations
    Department of Liver Surgery, Ren Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Search for articles by this author
  • Qiang Xia
    Correspondence
    Corresponding authors. Addresses: Dumont-UCLA Transplant Center, 77-120 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Tel.: +1 (323) 205-5156, (H. Ji), or Department of Liver Surgery, Ren Ji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Shanghai 200127, China (Q. Xia or N. Xu).
    Affiliations
    Department of Liver Surgery, Ren Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Search for articles by this author
  • Jerzy W. Kupiec-Weglinski
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA
    Search for articles by this author
  • Haofeng Ji
    Correspondence
    Corresponding authors. Addresses: Dumont-UCLA Transplant Center, 77-120 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Tel.: +1 (323) 205-5156, (H. Ji), or Department of Liver Surgery, Ren Ji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Shanghai 200127, China (Q. Xia or N. Xu).
    Affiliations
    Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA
    Search for articles by this author
  • Author Footnotes
    † These authors contributed equally to this work.

      Highlights

      • High graft YAP expression was correlated with well-preserved histology and improved hepatocellular function in human OLT.
      • YAP activation promoted downstream regenerative/anti-oxidative gene induction.
      • YAP activation diminished oxidative stress, necrosis/apoptosis, and suppressed the innate inflammatory response.
      • YAP activation suppressed extracellular matrix synthesis and hepatic stellate cell activation, and stopped fibrogenesis.
      • YAP activation failed to protect Nrf2-deficient mouse livers against IR-mediated tissue damage.

      Background & Aims

      Hepatic ischemia-reperfusion injury (IRI) is a major complication of hemorrhagic shock, liver resection and transplantation. YAP, a key downstream effector of the Hippo pathway, is essential for determining cell fate and maintaining homeostasis in the liver. We aimed to elucidate its role in IRI.

      Methods

      The role of YAP/Hippo signaling was systematically studied in biopsy specimens from 60 patients after orthotopic liver transplantation (OLT), and in a mouse model of liver warm IRI. Human biopsy specimens were collected after 2–10 h of cold storage and 3 h post-reperfusion, before being screened by western blot. In the mouse model, the role of YAP was probed by activating or inhibiting YAP prior to ischemia-reperfusion.

      Results

      In human biopsies, high post-OLT YAP expression was correlated with well-preserved histology and improved hepatocellular function at postoperative day 1–7. In mice, the ischemia insult (90 min) triggered intrinsic hepatic YAP expression, which peaked at 1–6 h of reperfusion. Activation of YAP protected the liver against IR-stress, by promoting regenerative and anti-oxidative gene induction, while diminishing oxidative stress, necrosis/apoptosis and the innate inflammatory response. Inhibition of YAP aggravated hepatic IRI and suppressed repair/anti-oxidative genes. In mouse hepatocyte cultures, activating YAP prevented hypoxia-reoxygenation induced stress. Interestingly, YAP activation suppressed extracellular matrix synthesis and diminished hepatic stellate cell (HSC) activation, whereas YAP inhibition significantly delayed hepatic repair, potentiated HSC activation, and enhanced liver fibrosis at 7 days post-IRI. Notably, YAP activation failed to protect Nrf2-deficient livers against IR-mediated damage, leading to extensive fibrosis.

      Conclusion

      Our novel findings document the crucial role of YAP in IR-mediated hepatocellular damage and liver fibrogenesis, providing evidence of a potential therapeutic target for the management of sterile liver inflammation in transplant recipients.

      Lay summary

      In the clinical arm, graft YAP expression negatively correlated with liver function and tissue damage after human liver transplantation. YAP activation attenuated hepatocellular oxidative stress and diminished the innate immune response in mouse livers following ischemia-reperfusion injury. In the mouse model, YAP inhibited hepatic stellate cell activation, and abolished injury-mediated fibrogenesis up to 7 days after the ischemic insult.

      Graphical abstract

      Keywords

      Linked Article

      • Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice
        Journal of HepatologyVol. 75Issue 1
        • Preview
          Severe fibrosis often leads to significant mortality as a result of liver failure and cirrhosis. Recent evidence arising in the Journal of Hepatology etc. shed light on the role of the mechanosensing Hippo/YAP/TAZ pathway during hepatic fibrosis.1–5 Those studies suggested that the YAP/TAZ pathway was activated in various mouse models of liver fibrosis and in human fibrotic liver. However, conflicting data exist for both positive and negative regulation of the YAP/TAZ pathway in liver fibrogenesis.
        • Full-Text
        • PDF
      • Reply to: “Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice”
        Journal of HepatologyVol. 75Issue 1
        • Preview
          We thank Dr. Xu et al. for their insightful letter1 and take advantage of this reply to clarify important aspects of our article,2 in which we employed a well-established mouse model of liver ischemia-reperfusion injury (IRI) to show that activation of YAP attenuated oxidative stress and innate immune responses in liver IRI. As activation of YAP prevented hepatocellular damage in liver IRI, it further mitigated IR-mediated liver fibrosis.
        • Full-Text
        • PDF
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Ji H.
        • Shen X.
        • Gao F.
        • Ke B.
        • Freitas M.C.
        • Uchida Y.
        • et al.
        Programmed death-1/B7-H1 negative costimulation protects mouse liver against ischemia and reperfusion injury.
        Hepatology. 2010; 52: 1380-1389
        • Ji H.
        • Zhang Y.
        • Shen Xd
        • Gao F.
        • Huang C.Y.
        • Abad C.
        • et al.
        Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: Immunomodulation by the cAMP-PKA pathway.
        Hepatology. 2013; 57: 1225-1237
        • Ji H.
        • Liu Y.
        • Zhang Y.
        • Shen Xd
        • Gao F.
        • Busuttil R.W.
        • et al.
        T-cell immunoglobulin and mucin domain 4 (TIM-4) signaling in innate immune-mediated liver ischemia-reperfusion injury.
        Hepatology. 2014; 60: 2052-2064
        • Duffy J.P.
        • Kao K.
        • Ko C.Y.
        • Farmer D.G.
        • McDiarmid S.V.
        • Hong J.C.
        • et al.
        Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors.
        Ann Surg. 2010; 252: 652-661
        • Evans H.M.
        • Kelly D.A.
        • McKiernan P.J.
        • Hübscher S.
        Progressive histological damage in liver allografts following pediatric liver transplantation.
        Hepatology. 2006; 43: 1109-1117
        • Ekong U.D.
        • Melin-Aldana H.
        • Seshadri R.
        • Lokar J.
        • Harris D.
        • Whitington P.F.
        • Alonso E.M.
        Graft histology characteristics in long-term survivors of pediatric liver transplantation.
        Liver Transpl. 2008; 14: 1582-1587
        • Scheenstra R.
        • Peeters P.M.
        • Verkade H.J.
        • Gouw A.S.
        Graft fibrosis after pediatric liver transplantation: ten years of follow-up.
        Hepatology. 2009; 49: 880-886
        • Schuppan D.
        • Afdhal N.H.
        Liver cirrhosis.
        Lancet. 2008; 371: 838-851
        • Mederacke I.
        • Hsu C.C.
        • Troeger J.S.
        • Huebener P.
        • Mu X.
        • Dapito D.H.
        • et al.
        Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.
        Nat Commun. 2013; 4: 2823
        • Martin K.
        • Pritchett J.
        • Llewellyn J.
        • Mullan A.F.
        • Athwal V.S.
        • Dobie R.
        • et al.
        PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis.
        Nat Commun. 2016; 7: 12502
        • Gabbiani G.
        The myofibroblast in wound healing and fibrocontractive diseases.
        J Pathol. 2003; 200: 500-503
        • Ide M.
        • Kuwamura M.
        • Kotani T.
        • Sawamoto O.
        • Yamate J.
        Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions.
        J Comp Pathol. 2005; 133: 92-102
        • Sunami Y.
        • Leithauser F.
        • Gul S.
        • Fiedler K.
        • Guldiken N.
        • Espenlaub S.
        • et al.
        Hepatic activation of IKK/NFkappaB signaling induces liver fibrosis via macrophage-mediated chronic inflammation.
        Hepatology. 2012; 56: 1117-1128
        • Pradere J.P.
        • Kluwe J.
        • Minicis S.
        • Jiao J.J.
        • Gwak G.Y.
        • Dapito D.H.
        • et al.
        Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice.
        Hepatology. 2013; 58: 1461-1473
        • Yimlamai D.
        • Christodoulou C.
        • Galli G.G.
        • Yanger K.
        • Pepe-Mooney B.
        • Gurung B.
        • et al.
        Hippo pathway activity influences liver cell fate.
        Cell. 2014; 157: 1324-1338
        • Dong J.
        • Feldmann G.
        • Huang J.
        • Wu S.
        • Zhang N.
        • Comerford S.A.
        • et al.
        Elucidation of a universal size-control mechanism in Drosophila and mammals.
        Cell. 2007; 130: 1120-1133
        • Yagi R.
        • Chen L.F.
        • Shigesada K.
        • Murakami Y.
        • Ito Y.
        A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator.
        EMBO J. 1999; 18: 2551-2562
        • Lee D.H.
        • Park J.O.
        • Kim T.S.
        • Kim S.K.
        • Kim T.H.
        • Kim M.C.
        • et al.
        LATS-YAP/TAZ controls lineage specification by regulating TGFbeta signaling and Hnf4alpha expression during liver development.
        Nat Commun. 2016; 7: 11961
        • Torre C.
        • Perret C.
        • Colnot S.
        Molecular determinants of liver zonation.
        Prog Mol Biol Transl Sci. 2010; 97: 127-150
        • Kim W.
        • Khan S.K.
        • Gvozdenovic-Jeremic J.
        • Kim Y.
        • Dahlman J.
        • Kim H.
        • et al.
        Hippo signaling interactions with Wnt/beta-catenin and Notch signaling repress liver tumorigenesis.
        J Clin Invest. 2017; 127: 137-152
        • Zhang N.
        • Bai H.
        • David K.K.
        • Dong J.
        • Zheng Y.
        • Cai J.
        • et al.
        The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.
        Dev Cell. 2010; 19: 27-38
        • Zhou D.
        • Conrad C.
        • Xia F.
        • Park J.-S.
        • Payer B.
        • Yin Y.
        • et al.
        Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.
        Cancer cell. 2009; 16: 425-438
        • Grijalva J.L.
        • Huizenga M.
        • Mueller K.
        • Rodriguez S.
        • Brazzo J.
        • Camargo F.
        • et al.
        Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration.
        Am J Physiol Gastrointest Liver Physiol. 2014; 307: G196-204
        • Kowalik M.A.
        • Saliba C.
        • Pibiri M.
        • Perra A.
        • Ledda-Columbano G.M.
        • Sarotto I.
        • et al.
        Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice.
        Hepatology. 2011; 53: 2086-2096
        • Mederacke I.
        • Dapito D.H.
        • Affo S.
        • Uchinami H.
        • Schwabe R.F.
        High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers.
        Nat Protoc. 2015; 10: 305-315
        • Ke B.
        • Shen X.D.
        • Zhang Y.
        • Ji H.
        • Gao F.
        • Yue S.
        • et al.
        KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants.
        J Hepatol. 2013; 59: 1200-1207
        • Jaeschke H.
        • Lemasters J.J.
        Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury.
        Gastroenterology. 2003; 125: 1246-1257
        • Berenguer M.
        • Schuppan D.
        Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.
        J Hepatol. 2013; 58: 1028-1041
        • Dechêne A.
        • Sowa J.P.
        • Gieseler R.K.
        • Jochum C.
        • Bechmann L.P.
        • El Fouly A.
        • et al.
        Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation.
        Hepatology. 2010; 52: 1008-1016
        • Tacke F.
        • Zimmermann H.W.
        Macrophage heterogeneity in liver injury and fibrosis.
        J Hepatol. 2014; 60: 1090-1096
        • Duffield J.S.
        • Forbes S.J.
        • Constandinou C.M.
        • Clay S.
        • Partolina M.
        • Vuthoori S.
        • et al.
        Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair.
        J Clin Invest. 2005; 115: 56-65
        • Fallowfield J.A.
        • Mizuno M.
        • Kendall T.J.
        • Constandinou C.M.
        • Benyon R.C.
        • Duffield J.S.
        • Iredale J.P.
        Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.
        J Immunol. 2007; 178: 5288-5295
        • Hellerbrand C.
        • Stefanovic B.
        • Giordano F.
        • Burchardt E.R.
        • Brenner D.A.
        The role of TGFβ1 in initiating hepatic stellate cell activation in vivo.
        J Hepatol. 1999; 30: 77-87
        • Seki E.
        • De Minicis S.
        • Osterreicher C.H.
        • Kluwe J.
        • Osawa Y.
        • Brenner D.A.
        • Schwabe R.F.
        TLR4 enhances TGF-beta signaling and hepatic fibrosis.
        Nat Med. 2007; 13: 1324-1332
        • Konishi T.
        • Schuster R.M.
        • Lentsch A.B.
        Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
        Am J Physiol Gastrointest Liver Physiol. 2018; 314: G471-482
        • Piersma B.
        • de Rond S.
        • Werker P.M.
        • Boo S.
        • Hinz B.
        • van Beuge M.M.
        • et al.
        YAP1 Is a driver of myofibroblast differentiation in normal and diseased fibroblasts.
        Am J Pathol. 2015; 185: 3326-3337
        • Mannaerts I.
        • Leite S.B.
        • Verhulst S.
        • Claerhout S.
        • Eysackers N.
        • Thoen L.F.
        • et al.
        The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.
        J Hepatol. 2015; 63: 679-688
        • Ma Q.
        Role of nrf2 in oxidative stress and toxicity.
        Annu Rev Pharmacol Toxicol. 2013; 53: 401-426
        • Ciamporcero E.
        • Daga M.
        • Pizzimenti S.
        • Roetto A.
        • Dianzani C.
        • Compagnone A.
        • et al.
        Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer.
        Free Radic Biol Med. 2018; 115: 447-457